Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards for its ADXS-HPV construct.
The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months.
"We are delighted to receive recognition for our Company's achievements in developing ADXS-HPV," commented Thomas A. Moore, Chairman & CEO of Advaxis. "Our team continues to bring our proprietary platform technology from the laboratory into the clinic and meet major milestones in development in HPV caused cancers and soon in prostate and breast cancer, as well."
The ViE Awards
The ViE Award nominees were voted on by those in the global vaccine industry and also judged by a panel of representatives from pharma, biotech, academia, government, non-governmental organizations (NGOs), and public health. Winners were announced at the annual ViE Awards on April 11, 2012 during the World Vaccine Congress in Washington, D.C., produced by Terrapinn.
The criteria used to judge this category are as follows:
-Vaccine candidate addresses current unmet medical needs
-Candidate shows significant potential for vast geographical and market reach
- Candidate possesses a novel mode of action or technology
-Progress made to date through clinical trials and/or achieved milestones
- Advanced efficacy, safety, and risk management data where appropriate
Judges specific comments on the winner included:
1. Has been shown to work at a rate that is greater than or equal to any other available treatment while being a fraction of the cost with no SAE. This vaccine also has implications across a wide range of diseases.
2. Revolutionary approach yet intuitively very simple and economical, safe and easy to administer, real breakthrough potential.
3. Its also worth noting in the wider industry vote, although not decisive, this company gained 40% of the 793 votes cast for this category
Well done Advaxis: ADXS-HPV – HPV !
http://blogs.terrapinn.com/vaccinenation/2012/04/12/winner-therapeutic-vaccine-advaxis-wvcusa-vie-awards/
